

7-30-08

IFW



Express Mail No.: EV 654 895 272US  
(Box 1 of 4; Refs. A86-A94, B01-B25)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman *et al.*

Confirmation No.: 2092

Application No.: 10/573,905

Group Art Unit: 1647

Filed: May 30, 2006

Examiner: DeBerry, Regina M.

For: TISSUE PROTECTIVE CYTOKINES FOR THE  
TREATMENT AND PREVENTION OF SEPSIS  
AND THE FORMATION OF ADHESIONS

Attorney Docket No.: 10165-042-999  
(Formerly: WP03-1 A04-US)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A01-A94, B01-B56, and C01-C402 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Copies of references A86-A94, B01-B25 are submitted in Box 1 under Express Mail No. EV654895272US; copies of B26-B56, C01-C09 are submitted in Box 2 under Express Mail No. EV654895286US; copies of C10-C229 are submitted in Box 3 under Express Mail No. EV654895290US and copies of C230-C402 are submitted in Box 4 under Express Mail No. EV654895309US.

Copies of references A01-A85 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(ii), the U.S. patents or U.S. patent application publications listed in an Information Disclosure

Statement in a patent application, regardless of the filing date of the application, need not be submitted.

The U.S. patent application listed as reference A91 is the U.S. national stage application of the international patent application listed as reference B26. Therefore, a copy of reference B26 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A91. The U.S. patent application listed as reference A93 is the U.S. national stage application of the international patent application listed as reference B33. Therefore, a copy of reference B33 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A93.

Should the Examiner require copies of any of the listed references that have not been provided, Applicants can provide such copies upon request.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

For the non-English language references B02, B07, B08, B12, B37, B42, B46, B53, C08, and C158 a concise explanation of relevance has been included with the respective reference according to the requirements set forth in MPEP 609.04(a) section III.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the mailing of a first Office Action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. However, should the Office determine otherwise, please charge any required fees to Jones Day deposit account no. 50-3013.

Respectfully submitted,

by: *Serghian Karbiel*  
Reg. No. 52,413

Date: July 29, 2008

*Laura A. Coruzzi*

30,742

Laura A. Coruzzi

(Reg. No.)

**JONES DAY**

222 East 41<sup>st</sup> Street

New York, New York 10017

Telephone Number: 212-326-3939

Fax No.: 212-755-7306

Enclosure



Express Mail No.: EV 654 895 290 US  
(Box 3 of 4; Refs. C10-C229)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Coleman *et al.*

Confirmation No.: 2092

Application No.: 10/573,905

Group Art Unit: 1647

Filed: May 30, 2006

Examiner: DeBerry, Regina M.

For: TISSUE PROTECTIVE CYTOKINES FOR THE  
TREATMENT AND PREVENTION OF SEPSIS  
AND THE FORMATION OF ADHESIONS

Attorney Docket No.: 10165-042-999  
(Formerly: WP03-1 A04-US)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A01-A94, B01-B56, and C01-C402 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Copies of references A86-A94, B01-B25 are submitted in Box 1 under Express Mail No. EV654895272US; copies of B26-B56, C01-C09 are submitted in Box 2 under Express Mail No. EV654895286US; copies of C10-C229 are submitted in Box 3 under Express Mail No. EV654895290US and copies of C230-C402 are submitted in Box 4 under Express Mail No. EV654895309US.

Copies of references A01-A85 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(ii), the U.S. patents or U.S. patent application publications listed in an Information Disclosure

Statement in a patent application, regardless of the filing date of the application, need not be submitted.

The U.S. patent application listed as reference A91 is the U.S. national stage application of the international patent application listed as reference B26. Therefore, a copy of reference B26 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A91. The U.S. patent application listed as reference A93 is the U.S. national stage application of the international patent application listed as reference B33. Therefore, a copy of reference B33 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A93.

Should the Examiner require copies of any of the listed references that have not been provided, Applicants can provide such copies upon request.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

For the non-English language references B02, B07, B08, B12, B37, B42, B46, B53, C08, and C158 a concise explanation of relevance has been included with the respective reference according to the requirements set forth in MPEP 609.04(a) section III.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the mailing of a first Office Action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. However, should the Office determine otherwise, please charge any required fees to Jones Day deposit account no. 50-3013. A duplicate copy of this sheet is enclosed.

Respectfully submitted, *by: Sebastian Karkhina*  
*Reg. No. 52,413*

Date: July 29, 2008

*Laura A. Coruzzi* 30,742  
\_\_\_\_\_  
Laura A. Coruzzi (Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
Telephone Number: 212-326-3939  
Fax No.: 212-755-7306

Enclosure

7-30-08

IFW



Express Mail No.: EV 654 895 309 US  
(Box 4 of 4; Refs. C230-C402)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Coleman *et al.*

Confirmation No.: 2092

Application No.: 10/573,905

Group Art Unit: 1647

Filed: May 30, 2006

Examiner: DeBerry, Regina M.

For: TISSUE PROTECTIVE CYTOKINES FOR THE  
TREATMENT AND PREVENTION OF SEPSIS  
AND THE FORMATION OF ADHESIONS

Attorney Docket No.: 10165-042-999  
(Formerly: WP03-1 A04-US)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A01-A94, B01-B56, and C01-C402 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Copies of references A86-A94, B01-B25 are submitted in Box 1 under Express Mail No. EV654895272US; copies of B26-B56, C01-C09 are submitted in Box 2 under Express Mail No. EV654895286US; copies of C10-C229 are submitted in Box 3 under Express Mail No. EV654895290US and copies of C230-C402 are submitted in Box 4 under Express Mail No. EV654895309US.

Copies of references A01-A85 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(ii), the U.S. patents or U.S. patent application publications listed in an Information Disclosure

Statement in a patent application, regardless of the filing date of the application, need not be submitted.

The U.S. patent application listed as reference A91 is the U.S. national stage application of the international patent application listed as reference B26. Therefore, a copy of reference B26 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A91. The U.S. patent application listed as reference A93 is the U.S. national stage application of the international patent application listed as reference B33. Therefore, a copy of reference B33 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A93.

Should the Examiner require copies of any of the listed references that have not been provided, Applicants can provide such copies upon request.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

For the non-English language references B02, B07, B08, B12, B37, B42, B46, B53, C08, and C158 a concise explanation of relevance has been included with the respective reference according to the requirements set forth in MPEP 609.04(a) section III.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the mailing of a first Office Action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. However, should the Office determine otherwise, please charge any required fees to Jones Day deposit account no. 50-3013. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

*by: Sebastian Karbiel*  
*Reg. No. 52,413*

Date: July 29, 2008

*Laura A. Coruzzi* 30,742  
Laura A. Coruzzi (Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
Telephone Number: 212-326-3939  
Fax No.: 212-755-7306

Enclosure

7-30-08

IFW



Express Mail No.: EV 654 895 286 US  
(Box 2 of 4; Refs. B26-B56; C01-C09)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Coleman *et al.*

Confirmation No.: 2092

Application No.: 10/573,905

Group Art Unit: 1647

Filed: May 30, 2006

Examiner: DeBerry, Regina M.

For: TISSUE PROTECTIVE CYTOKINES FOR THE  
TREATMENT AND PREVENTION OF SEPSIS  
AND THE FORMATION OF ADHESIONS

Attorney Docket No.: 10165-042-999  
(Formerly: WP03-1 A04-US)

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.56 AND §1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and §1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to references A01-A94, B01-B56, and C01-C402 listed on the attached revised form PTO 1449 entitled "List of References Cited by Applicant."

Copies of references A86-A94, B01-B25 are submitted in Box 1 under Express Mail No. EV654895272US; copies of B26-B56, C01-C09 are submitted in Box 2 under Express Mail No. EV654895286US; copies of C10-C229 are submitted in Box 3 under Express Mail No. EV654895290US and copies of C230-C402 are submitted in Box 4 under Express Mail No. EV654895309US.

Copies of references A01-A85 are not submitted herewith because they are U.S. patents or U.S. patent application publications. Pursuant to 37 C.F.R. § 1.98 (a)(2)(ii), the U.S. patents or U.S. patent application publications listed in an Information Disclosure

Statement in a patent application, regardless of the filing date of the application, need not be submitted.

The U.S. patent application listed as reference A91 is the U.S. national stage application of the international patent application listed as reference B26. Therefore, a copy of reference B26 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A91. The U.S. patent application listed as reference A93 is the U.S. national stage application of the international patent application listed as reference B33. Therefore, a copy of reference B33 is not submitted herewith because it is identical and therefore cumulative to the U.S. patent application A93.

Should the Examiner require copies of any of the listed references that have not been provided, Applicants can provide such copies upon request.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

For the non-English language references B02, B07, B08, B12, B37, B42, B46, B53, C08, and C158 a concise explanation of relevance has been included with the respective reference according to the requirements set forth in MPEP 609.04(a) section III.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(b) before the mailing of a first Office Action on the merits. Therefore, no fee is believed to be due for this Information Disclosure Statement. However, should the Office determine otherwise, please charge any required fees to Jones Day deposit account no. 50-3013. A duplicate copy of this sheet is enclosed.

Date: July 29, 2008

Respectfully submitted,

*by: Subroshan Karbhick*  
*Reg. No. 52,413*

*Laura A. Coruzzi*

30,742

Laura A. Coruzzi

(Reg. No.)

**JONES DAY**

222 East 41<sup>st</sup> Street

New York, New York 10017

Telephone Number: 212-326-3939

Fax No.: 212-755-7306

Enclosure